A partial gene product was identified in a pedigree with hemophilia B due to a partial deletion of the Factor IX gene (Chen, S.-H., S. Yoshitake, P. F. Chance, G. L. Bray, A. R. Thompson, C. R. Scott, and K. Kurachi, 1985 , J. Clin. Invest., 76:2161-2164. Levels of this mutant protein in plasma of affected family members studied ranged from 24 to 36 ng/ml (0.6-0.9 U/dl or percent of normal) by a solid-phase immunoassay which is sensitive and specific for the calcium-dependent conformation of human Factor IX. No Factor IX antigen could be detected in patients' plasmas by a non-calcium-requiring monoclonal antiFactor IX antibody (<2 ng/ml). The unconcentrated urine from the five affected family members and four obligate heterozygotes tested contained calcium-dependent Factor IX antigen levels ranging from 64 to 160 ng/ml (1.6-4.0 U/dl) and from 10 to 68 ng/ml (0.25-1.7 U/dl), respectively. Of nine normal volunteers screened, three had detectable calcium-dependent antigen in unconcentrated first morning-voided urines with 9.6-16.8 ng/ml (0.244.42 U/dl), while the remaining six had detectable urinary antigen only after a 10-fold concentration.
Introduction
Hereditary deficiency of Factor IX, hemophilia B, is an X-linked disorder characterized by recurrent bleeding episodes. Approx-A preliminary report of this work has appeared in abstract form (1985. imately one-third ofaffected individuals have severe disease and exhibit spontaneous bleeding without a history of antecedent injury. While the clinical features of hemophilia A (Factor VIII deficiency) and hemophilia B are virtually identical, they are distinguished by the deficient clotting factor and by the blood component used for replacement therapy. Another distinction is the prevalence of acquired inhibitors. Approximately 15% of individuals with severe hemophilia A develop anti-Factor VIII antibodies after therapy, usually by early adulthood (1) . In contrast, the incidence of inhibitors in hemophilia B is decidedly lower, occurring in 2.5% (1), or less, of severely affected individuals. One explanation for a lower incidence is that most patients with hemophilia B have at least low levels of Factor IX antigen in their plasma (2, 3) .
Direct gene analysis has been applied to the study of hemophilia B patients with inhibitors. DNA from six inhibitor patients in five different pedigrees has demonstrated gross deletions in the Factor IX gene among all but one (4, 5) . More recently, Chen et al. (6) have identified a partial gene deletion occurring in two cousins with severe hemophilia B and no inhibitor. This deletion, 1 I0 kilobases (kb)' in length, is located in the middle third of the Factor IX gene, with those regions flanking the deletion appearing grossly intact by Southern blot analysis. Although nucleotide sequencing has not yet localized the deletion site (6) , it is reasonable to assume that the portion of the gene 5' to the deletion is structurally intact. This portion of the gene includes the signal for peptide initiation and a leader sequence in the first exon, the pro-sequence and divalent metal binding, y-carboxyglutamyl (Gla), domain as coded for by the second and third exons, and the first of two epidermal growth factor homologous regions as coded for by the fourth exon (2) . It was hypothesized that affected individuals from this pedigree might synthesize a partial gene product, a portion ofwhich would consist of the intact Gla region, capable of assuming its normal conformational change in the presence of calcium. If secreted into plasma, the mutant gene product should be of sufficiently low molecular weight to be filtered by the kidneys and excreted into urine.
To screen for this abnormal Factor IX protein, a sensitive solid-phase immunoassay, which is highly specific for the calcium-dependent2 conformation of native Factor IX, was employed. Low levels of Factor IX were detected in the baseline plasma from four patients and in the urines from five patients and four obligate heterozygotes tested. An unanticipated finding was the presence oftrace amounts ofFactor IX antigen in urines 1 . Abbreviations used in this paper: CNBr, cyanogen bromide; kb, kilobases; MES, 2(N-morphilino)ethane sulfonic acid. 2. For purposes of this manuscript, the term calcium-dependent refers to the conformation of native Factor IX antigen and its levels by immunoradiometric assays in the presence of calcium; the term calciumrequiring is applied to polyclonal antibody fractions or monoclonal antibodies that will only interact with Factor IX antigen when it has assumed its calcium-dependent conformation. from normal individuals. Normal and hemophilic urinary Factor IX antigens were then purified and partially characterized.
Methods
Materials. Chemicals were purchased from the following sources: acrylamide from Serva Fine Biochemicals Inc., Garden City Park, NY; sodium dodecyl sulfate-polyacrylamide gel electrophoresis low molecular weight protein standards, Coomassie Blue R-250, sodium dodecyl sulfate, N,N,N',N'-tetramethylethylenediamine, nitrocellulose, and ammonium persulfate from Bio-Rad Laboratories, Richmond, CA; bovine albumin (fraction V), dithiothreitol, rabbit brain cephalin, trizma base, 2(N-morpholino)ethane sulfonic acid (MES), and heparin from Sigma Chemical Co., St. Louis, MO; bis-acrylamide and chloramine T Human Factor IX was purified as described (7) . For some studies, a preparation generously provided by Dr. Walter Kisiel, Department of Biochemistry, University of New Mexico, Albuquerque, NM, was used. These preparations migrated as single bands on polyacrylamide gels in the presence of sodium dodecyl sulfate. Factor IX was radioiodinated by the chloramine T method as described (7), but modified to employ 400 liCi Na125I in a 40-ul vol and a 60-s reaction time. The average radioactivity of this preparation was 9.0 X 101 cpm/hug of protein. Coupling of the Factor IX preparation to CNBr-activated Sepharose 4B (1.4 mg/ml wet gel) was performed according to the manufacturer's instructions. Normal citrated human plasma was obtained from volunteer blood donors and consisted of a pool of at least ten.
Patient and heterozygote characteristics. All affected individuals belong to the same generation (III) and are the progeny of four sisters (Fig.  1) . Their bleeding episodes respond to Factor IX concentrate and each patient has been multiply transfused for bleeding events up to 35 times per year. To date, none has exhibited chronic complications of hemophilia. Despite the partial gene deletion (6) , plasma samples from the five affected individuals available for study (111-4, III-6-9) tested negatively for the presence of Factor IX inhibitory activity (8) . None of the five obligate heterozygotes (I-1, 11-2, II-4-6) has experienced abnormal bleeding and the four heterozygotes tested (I-1, 11-4-6) are also heterozygous for the Taq I restriction fragment length polymorphism found in affected members (6 (6) . (6) , whereas family members III-3 and III-5 will not be having DNA analysis until they are older.
Samples and clotting assays. Levels of Factor IX procoagulant activity in citrated plasma were determined by a modification of the one-stage, kaolin-activated partial thromboplastin time (9) employing congenitally deficient substrate plasma with <40 ng/ml (1 U/dl) Factor IX antigen. Inhibitor titer assays were performed using citrated plasma, employing the method described by Kasper (8) , but were modified by incubating for only 30 min before assay. The control incubation consisted of equal volumes of normal plasma and 0.15 M NaCl. An IgG fraction was prepared from plasma from patient 111-6, by employing a modification of methods described by Kessler (10) . Briefly, 15 ml heparinized plasma, previously adsorbed with one-tenth volume Al(OH)3 suspension, was applied to a 1.5 X 0.9-cm staphylococcal protein A CL-Sepharose 4B column, equilibrated in and washed with 0.1 M NaCl, 50 mM Tris, pH 7.5. An IgG fraction was eluted from the column with 3 M KSCN and subsequently dialyzed for 48 h against 2 liters 0.1 M NaHCO3, pH 9.5, before assay.
Preparation ofpurified polyclonal anti-human Factor IX antibody fractions. Rabbit anti-human Factor IX antibody was prepared by a modification of previously described methods (7) . For immunization purposes, 5 mM CaCI2 (final concentration) was added to the Factor IX preparation before being emulsified in Freund's adjuvants. Immune sera obtained after secondary immunization were fractionated by affinity chromatography similar to the procedure of Liebman et al. (1 1), employing a 1 X 9.5-cm bed volume column of Factor IX-Sepharose 4B previously equilibrated in 0.1 M NaCl, 50 mM Tris, pH 7.5, with 5 mM CaCI2. Calcium-requiring anti-Factor IX fractions were eluted in the same buffer with 5 mM EDTA instead ofCaCl2. Non-calcium-requiring fractions that remained bound to the column were then eluted in 0.1 M glycine-HCl, pH 2.5, pooled, and dialyzed overnight against 1 liter 0.1 M NaCI, 50 mM Tris, pH 7.5.
Purified calcium-requiring antibody fractions were pooled and concentrated approximately fourfold by pressure dialysis in a 10-ml ultrafiltration cell with a PM-30 membrane (Amicon Corp., Danvers, MA). The concentrated preparation was radioiodinated by the chloramine T method to an average radioactivity of 1.3 X 104 cpm/ug protein or was coupled to CNBr-activated Sepharose 4B (0.6 mg protein/ml wet gel). The polyclonal, non-calcium-requiring anti-Factor IX preparation was radioiodinated to an average radioactivity of 2.9 X I04 cpm//g protein.
Monoclonal antibodies. A non-calcium-requiring monoclonal antiFactor IX which binds to an epitope on the heavy chain of Factor IXa (3) was employed as the solid-phase antibody in some immunoassays (see below) and was also radioiodinated by the chloramine T method (7) using 1-min incubations (2.7 X 103 cpm/,ug protein). A monoclonal calcium-requiring anti-factor IX which reacts with a Factor IXa light chain epitope, was generously provided by Dr. Kenneth Smith, Departments of Pathology and Medicine, University of New Mexico, Albuquerque, NM (12) . The antibody preparation was coupled to CNBractivated Sepharose 4B (3.0 mg/ml wet gel) for immunoaffinity purification of urinary Factor IX antigen as described below.
Concentration and purification ofurinary Factor IX antigen. Efforts Partial Hemophilic Factor IX Protein 1195 to purify calcium-dependent antigen from the plasma of affected individuals were limited by the low levels in their plasma and by the amount of plasma available. Insofar as Factor IX antigen was present at higher levels in urine than in plasma from these individuals, mutant Factor IX was concentrated and purified from urine.
Urine was sampled as a first morning void in all individuals studied except for four patients and two obligate heterozygotes from whom up to 2 liters of urine were collected into 1-5 mM benzamidine (final concentration) for up to 5 d; the latter was stored at 40C during the collection period. Among affected family members, no Factor IX concentrate was infused for a period of at least 7 d before the beginning of the urine collection and throughout the collection period. Urine was centrifuged at 12,000 g for 10 min in order to render it poor ofcells, salts, and debris. Supernatant urine was subsequently frozen at -70'C until use. Upon thawing, it was occasionally necessary to centrifuge the urine to remove precipitated salts. Urine pHs were between 5.3 and 6.8.
Single-void urines were concentrated 10-100-fold in 10-ml or 50-ml ultrafiltration cells. For the larger volume preparations, urine was concentrated 100-200-fold using first a 375-ml and then a 50-ml ultrafiltration cell. Either PM-10 or YM-10 Diaflo membranes (Amicon Corp., Scientific Systems Div., Danvers, MA) were used. After initial concentration, the urine was twice diluted 10-fold with 0.1 M NaCl, 50 mM Tris, pH 7.5, containing 0.01% bovine serum albumin and I mM benzamidine and the volume subsequently reduced by pressure dialysis.
CaCl2 was added at a final concentration of 10 mM to each concentrated urine sample before affinity chromatography.
For immunoaffinity purification, either a polyclonal, calcium-requiring anti-Factor IX Sepharose 4B column (1.5 X 6.4 cm) or a monoclonal calcium-requiring anti-Factor IX Sepharose 4B column (1.4 X 5.7 cm) was employed. These were equilibrated with 50 mM Tris, pH 7.5, 5 mM CaC12 containing 0.1 M NaCI or 0.5 M NaCl, respectively. The columns were washed with the respective calcium-containing equilibration buffers until the absorbance at 280 nm of the column effluent was <0.02. The columns were then washed with 20-30 ml of 0.1 M NaCl, 50 mM Tris, pH 7.5, 2 mM CaCl2. Factor IX antigen was eluted in 0.1 M NaCl, 50 mM Tris, pH 7.5, 5 mM EDTA. l-ml fractions ofthe EDTA eluate were collected and screened for antigen by polyclonal calciumrequiring and monoclonal non-calcium-requiring immunoradiometric assays described below. Upon completion of each stepwise calcium-dependent adsorption and EDTA elution of urinary Factor IX antigen, the columns were washed with 1.0 M NaCI, 50 mM Tris, pH 7.5, 5 mM EDTA and, subsequently, the equilibration buffer. For some studies, antigen-containing fractions were pooled and concentration attempted by ultrafiltration using a YM-2 filter (Amicon Corp.).
Immunoradiometric assays. Levels ofurinary factor IX antigen were determined by modifications ofrecently described assays (3, 13) . Briefly, monoclonal non-calcium-requiring, anti-Factor IX or polyclonal calcium-requiring anti-Factor IX were diluted 200-fold in 0.1 M Na HCO3, pH 9.5, before being adsorbed to microtiter wells (Imulon-l Removastrip; Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, VA). Polyclonal non-calcium-requiring anti-Factor IX was diluted 80-fold and monoclonal calcium-requiring antibody was diluted 20-fold in the bicarbonate buffer before adsorption to wells. 50 mM Tris, pH 7.5, was substituted for phosphate in all buffer solutions used for sample dilution and washes; where indicated, these contained 5 mM CaC12. Dilutions of normal plasma and test plasmas or urines were incubated overnight in antibody-coated wells and were followed by a 6-h incubation with radiolabeled antibody. Patient plasma and urine samples were run on at least two separate occasions for each assay; at least four dilutions of patient plasma or urine were run and compared with data obtained from a simultaneously run standard curve of pooled normal human plasma. Data were plotted as log dilution vs. logistic probability ofpercent counts per minute bound in each well. Coefficients of variation for duplicate determinations were <7%; nonspecific binding was <1%.
Gel electrophoresis. Electrophoresis was performed in the presence of sodium dodecyl sulfate on 10% polyacrylamide gels as described by Weber and Osborn (14) ; for some experiments, slab gels were prepared and run as previously described (3) . Polyacrylamide slabs were blotted electrophoretically onto nitrocellulose paper in a methanol-containing Table I for all family members studied. Procoagulant activities and calciumdependent antigen levels among the five obligate heterozygotes ranged from 1.2 to 3.0 ug/ml and from 1.3 to 2.7 gg/ml, respectively. Non-calcium-dependent antigen levels as determined by radioimmunoassay (7), were from 1.3 to 3.5 ,ug/ml. Baseline plasmas from the four affected family members tested exhibited <1% of normal procoagulant activity while their calcium-dependent antigen levels were readily measurable with levels between 24 and 36 ng/ml. Non-calcium-dependent antigen levels determined from identical plasma samples were borderline to undetectable (<4.0 to 9.2 ng/ml) and only background radioactivity (<2.0 ng/ml) was noted in an immunoradiometric assay specified, levels are from assays using polyclonal antibody fractions as both the solid-phase and labeled species (as described in the experimental section and reference 13). Normal, citrated plasma pools contain 100 U/dl which corresponds to 4 ng/ml Factor IX antigen. Family members are as represented in Fig. 1 . * Determined by radioimmunoassay with polyclonal rabbit anti-Factor IX (7). f Mean of three separate first morningvoided specimens (range was 10-20 ng/ml). § The non-calcium-requiring polyclonal antibody fraction does show slightly more binding in the presence of calcium (19) such that the plasma levels observed may simply reflect presence of the calcium-dependent conformational (Gla) region in these samples. None of the affected members' plasmas or urines (the latter, even after concentration 100-fold) contained non-calcium-dependent antigen using immunoradiometric assay with the monoclonal antibody (3) which was sensitive to 2 ng/ml (see text). "l A perinatal cord plasma sample previously tested was thawed and contained 20 ng/ml calcium-dependent and 4 ng/ml non-calcium-dependent IX:Ag by assays with polyclonal antibody fractions.
using the monoclonal non-calcium-requiring antibody for the solid phase and '25I-polyclonal calcium-requiring anti-Factor IX in the final incubation.
Urinary Factor IX antigen levels. Levels of urinary Factor IX antigen as determined by calcium-dependent immunoradiometric assay range from 64 to 160 ng/ml among those affected individuals studied (Table I) . Antigen levels were measurable in the unconcentrated urine of all four obligate heterozygotes tested (I-1, 1I-4-6); these ranged from 10 to 68 ng/ml. Unconcentrated urine was studied from two female family members (III-3 and 111-5) whose carrier status had not yet been determined. Family member 111-3 exhibited urinary calcium-dependent antigen levels from 10 to 20 ng/ml in three different urine samples while antigen was undetectable in a single first morning-voided specimen from her female sibling (member 111-5). Calcium-dependent Factor IX antigen could be detected in unconcentrated urine from three normal volunteers (10-17 ng/ml). In six other normal subjects, antigen was only detectable after 10-fold concentration where levels were between 10 and 60 ng/ml.
Immunoassays in which the non-calcium-requiring monoclonal anti-Factor IX was employed as the adsorbing antibody, and 1251I-polyclonal calcium-requiring anti-Factor IX was employed as the labeling antibody did not detect antigen in urine from affected individuals even after 200-fold concentration and immunoaffinity purification as described in Methods. The antigenic determinant to which this non-calcium-requiring monoclonal antibody binds was detectable at a level of 480 ng/ ml in concentrated and immunoaffinity purified urine from the one normal subject tested. The same normal preparation (-500-fold concentrated) had 1.72 gg/ml by the calcium-dependent immunoassay with polyclonal antibody.
Concentration and immunoaffinity purification of urinary
Factor IX antigen. In preliminary studies employing pressure dialysis as a means of concentrating urine, it was found that nearly all of the urinary Factor IX antigen, as determined by calcium-dependent immunoradiometric assay, was retained by membranes with a 10,000-mol-wt exclusion pore size. Urines from four patients (III-4, 111-6, 111-8, III-9) and four heterozygotes (I-1, 11-4-6) were concentrated 100-200-fold with a yield ofFactor IX antigen which was 70-95% of the starting total antigen units (Table II) .
In five separate calcium-dependent adsorption-EDTA elutions of urinary Factor IX antigen (two affected individuals, two ieterozygotes, and one normal subject), yields of caladditional higher molecular weight species were noted on auendent antigen in the EDTA eluate varied from 30 to toradiographs ofall unreduced patient samples. Reduced antigen e total number of Factor IX antigen units applied to from normal urine migrated as a broad, 1 5,000-20,000-mol-wt in. Void volumes and washes only contained up to 5% band. Nonreduced normal urinary Factor IX antigen migrates al starting urinary Factor IX antigen.
as four distinct bands with mol wts ranging from 24,000 to icterization of urinary Factor IX antigen by Western 62,000. Interestingly, reduced samples of urinary Factor IX anmmunoaffinity-purified urinary Factor IX antigen was tigen from the four obligate carriers tested (I-1, 11-4-6) demto polyacrylamide slab gel electrophoresis, blotted onto onstrated both the normal 1 5,000-20,000-mol-wt band as well ilose, and radiolabeled as described in Methods. Lanes as a more prominent 36,000-mol-wt species characteristic of ith '251-non-calcium-requiring monoclonal anti-Factor reduced patient urinary Factor IX. 100-fold concentrated urine to demonstrate any antigen in urine from affected infrom family members II-l and 111-3 were electrophoresed fol- Fig. 2 shows typical autoradiographs obtained after lowing reduction and demonstrated only the normal 15,000-ling of Western blots with 1251-polyclonal calcium-re-20,000-mol-wt band (not shown).
iti-Factor IX. After reduction ofpurified urinary Factor Incubations ofFactor IX in urines. To determine the stability ns, '25I-polyclonal calcium-requiring anti-Factor IX of Factor IX's size and antigenicity in urine, trace amounts of a single band of -36,000 mol wt from the urines of '251-labeled normal isolated protein were incubated in two norted individuals. A 62,000-mol-wt band as well as an mal, one heterozygote, or three patient urines for 4 h at 37°. After reduction and electrophoresis on 10% polyacrylamide slab gels in sodium dodecyl sulfate, all of the '251-Factor IX samples two antibody preparations was essentially unaltered. Thus, the antigenicity ofthe calcium-dependent epitopes in Factor IX was Characterization of urinary Factor IX antigen by Western reduced by incubation at 37°at pHs just below those found in Concentrated and immunoaffinity-purified normal and hethe urine samples, but was unaltered in the actual urine samples antigen were electrophoresed in polyacrylamide slab gels, studied.
blotted, and autoradiographed after labeling with '5I-polyclonal calcium-dependent anti-Factor IX. Lanes 1 and 2 represent urinary Factor IX antigen from an affected family member (111-9), electrophoresed without or after reduction, respectively. The single 36,000-molwt band observed in lane 2 was noted in the three other affected family members studied, as were variable amounts of the two higher molecular weight species (lane 1) in blots of unreduced samples. (20) . Thus, the low levels of both plasma and urinary Factor IX antigen in these patients are best explained by decreased secretion from the hepatocytes or increased reticulo-endothelial processing of the mutant gene product.
The structure of the mutant Factor IX remains to be determined. Its reaction with antibodies specific for the calcium-dependent conformation argues that the amino-terminal (Gla) region, as a product of the second and third exons, is represented. Considerations of the polypeptide portion carboxy-terminal to the deletion site, however, must account for the size ofthe urinary fragments observed both before and after reduction of disulfide bonds. The most simple explanation of the defect is that exons VII and VIII are transcribed normally. A 36,000-mol-wt mutant Factor IX would be predicted from the loss of Asn-linked carbohydrate and a quarter of the amino acid sequence. Such a species would possess a free, unpaired sulfhydryl group at residue 289 (Fig. 3) . A second mechanism to consider is a frame shift. This would actually be predicted since exon IV ends with the first base of a triplet which normally includes the first two bases of exon V to form the codon for residue 85; exon VII begins in phase with a complete triplet (16, 17) . A new cysteine residue would be coded for in the second, shifted position. However, because the sixth, shifted codon would be TAA (a stop signal) the resulting peptide should only have a molecular weight of around 9,000. A third possibility is a new splice junction, occurring where the introns on either side of the deletion join. Here, a new nonsense peptide might be specified to compose the carboxy-terminal portion ofthe species observed; it too could contain an unpaired cysteine which could bind to other peptides. Disulfide formation would probably occur within the hepatocyte and could not be accounted for by simple dimers of a 36,000-mol-wt species (Fig. 2) . Unfortunately, there is insufficient purified mutant protein for structural analysis. It is anticipated that determination of the exact nucleotide base sequence 5' and 3' to the deleted segment (6), will allow prediction of the mutant carboxy-terminal structure. The urinary species could then serve as a reagent to help localize properties of Factor IX that either are or are not represented in the partial protein.
The detection ofFactor IX antigen in the concentrated urines from normal subjects was surprising. Previous radioimmunoassays (20-40-fold less sensitive than current methods) found that some patients with nephrotic syndrome, but not normal individuals, excrete detectable Factor IX antigen (21; Thompson, A. R., unpublished data, 1980). Furthermore, levels from calcium-dependent immunoassays suggest that these determinants are represented to a greater extent in normal urine than are epitopes recognized by non-calcium-requiring antibodies. This may be analogous to the amino-terminal fragment ofprothrombin which has recently been detected in normal urines and at higher levels in urines from pregnant women (22) . The latter could be due to the amniotic fluid serving as a reservoir for the prothrombin fragment (13) .
The calcium-dependent Factor IX urinary metabolites from normal individuals were present in lower concentrations than in patient urines. In addition, the normal antigen was qualitatively distinct from the hemophilic urinary antigen on electrophoresis (Fig. 2 ) and in reactivity with the non-calcium-requiring monoclonal antibody to Factor IX. This antibody recognizes an antigenic determinant on the heavy chain ofFactor IXa (3) which was detectable in purified normal, but not patient, urine fractions. The latter remained <2 ng/mg in patient samples concentrated 200-fold. These data suggest that the heavy chain epitope for this antibody resides somewhere between residues 181 and 195 of the native protein; alternatively, the antigenic determinant for this monoclonal antibody may be masked, or is simply absent due to altered transcription 3' to the deleted gene segment.
The Western blots of purified urinary antigen from the four obligate heterozygotes studied share features found on radiolabeled blots from both normal and patient urines (Fig. 2) . These shared features support the finding that Factor IX DNA from both the normal and hemophilic genes is expressed in these women and results in a pattern that is a hybrid of normal and patient blotted material. Family member II-1 is a known, nonheterozygote by virtue of the fact that she does not manifest the linked Taq 1 restriction fragment length polymorphism which her sisters and mother do (6) . Both she and her niece (III-3, Fig.  1 ), demonstrate only normal urinary Factor IX fragments on autoradiographs. The youngest female (III-5) lacks detectable calcium-dependent antigen in unconcentrated urine whereas the four obligate heterozygotes tested all had at least 10 ng/ml. Although DNA samples on subjects III-3 and III-5 have not been studied, the immunoassays demonstrate that analysis of urine samples can be used to recognize heterozygosity for the hemophilic gene in this family. Furthermore, such testing is more sensitive and specific than either Factor IX clotting activity or antigen level determinations from plasma samples of these women.
